Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Cash from Financing Activities (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Cash from Financing Activities for 7 consecutive years, with $15.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 791.51% to $15.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $58.8 million, a 126.11% increase, with the full-year FY2025 number at $45.0 million, down 25.43% from a year prior.
  • Cash from Financing Activities was $15.5 million for Q4 2025 at Outlook Therapeutics, up from $11.6 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $18.4 million in Q1 2025 to a low of $1.7 million in Q4 2024.